Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects

• Main Authors: Yuankui Zhu (Author), Ke Wang (Author), Linghe Yue (Author), Dianbao Zuo (Author), Junfeng Sheng (Author), Sina Lan (Author), Zilong Zhao (Author), Shuang Dong (Author), Sheng Hu (Author), Xin Chen (Author), Mingqian Feng (Author)
• Format: Book
• Published: Elsevier, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Chimeric antigen receptor (CAR)-modified T cell therapy has achieved remarkable efficacy in treating hematological malignancies, but it confronts many challenges in treating solid tumors, such as the immunosuppressive microenvironment of the solid tumors. These factors reduce the antitumor activity...